Form 8-K - Current report:
SEC Accession No. 0001193125-22-314745
Filing Date
2022-12-29
Accepted
2022-12-29 16:06:00
Documents
13
Period of Report
2022-12-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d411465d8k.htm   iXBRL 8-K 26931
2 EX-10.1 d411465dex101.htm EX-10.1 83862
  Complete submission text file 0001193125-22-314745.txt   253116

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tpst-20221223.xsd EX-101.SCH 2857
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tpst-20221223_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tpst-20221223_pre.xml EX-101.PRE 11266
7 EXTRACTED XBRL INSTANCE DOCUMENT d411465d8k_htm.xml XML 3367
Mailing Address 7000 SHORELINE COURT SUITE 275 SOUTH SAN FRANCISCO CA 94080
Business Address 7000 SHORELINE COURT SUITE 275 SOUTH SAN FRANCISCO CA 94080 415-798-8589
Tempest Therapeutics, Inc. (Filer) CIK: 0001544227 (see all company filings)

EIN.: 451472564 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35890 | Film No.: 221498901
SIC: 2834 Pharmaceutical Preparations